Comparison
Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are the two most popular GLP-1 family medications for weight loss. Semaglutide is the active ingredient in Wegovy and Ozempic, while tirzepatide powers Zepbound and Mounjaro. Understanding the differences helps you have a better conversation with your doctor.
| Category | Semaglutide | Tirzepatide | Winner |
|---|---|---|---|
| Mechanism | GLP-1 agonist only | GLP-1 + GIP dual agonist | Tirzepatide |
| Average weight loss | 12-15% of body weight | 18-21% of body weight | Tirzepatide |
| Availability | Easier to find | Supply improving | Semaglutide |
| Insurance coverage | More established coverage | Catch-up phase | Semaglutide |
| Side effect profile | Well-documented, manageable | Slightly higher GI side effects | Semaglutide |
| Brand names | Wegovy, Ozempic | Zepbound, Mounjaro | Tie |
| Compounded availability | Widely available compounded | Widely available compounded | Tie |
| Best for | First-time GLP-1 users, insured patients | Patients wanting maximum results | Tie |
Final verdict
Tirzepatide targets two hormone receptors instead of one, which translates to stronger average weight loss. But semaglutide has more real-world data, is often easier to find at pharmacies, and may be covered by more insurance plans. Both are excellent options.